RedHawk Obtains Exclusive U.K. Distribution Rights
YOUNGSVILLE, LA / ACCESSWIRE / February 2, 2016 / RedHawk Holdings Corp. (IDNG) ("RedHawk" or the "Company") announced today that RedHawk Medical Products U.K. Ltd. has entered into a contract for the exclusive distribution rights to WoundClot Surgical - Advanced Bleeding Control ("WoundClot") in the United Kingdom. WoundClot, developed and manufactured in Israel by Core Scientific Creations Ltd., is the first Class III medical device, fully implantable surgical hemostat designed to stop moderate to severe arterial and venous hemorrhage without the need to compress directly onto the wound.
WoundClot, made from cellulose, has been uniquely engineered and manufactured with a patented molecular structure, designed to entrap platelets and coagulants in a modified physical molecular matrix. This specific design creates a haemodynamic polymer membrane with high adherence and resilience properties that is able to both withstand extremely high pressure bleeds and immediately reduce blood flow. Simultaneously, the specifically designed functional molecular groups transform to enhance and activate the natural coagulation processes up to five times more efficiently than existing available products. Once the bleeding has stopped and the coagulation cascade has formed, the product can easily be removed, if desired, without disrupting the already-formed clot. Additionally, unlike other available products on the market, WoundClot is fully bio-absorbable and bio-degradable and, if needed, can be left in the wound to degrade safely within seven days.
This recently-approved revolutionary technology is currently being used by Israeli first responders and surgeons worldwide. WoundClot is in the final stages of acceptance and approval by the United States military and is currently being field-tested by the Israel Defense Forces and other militaries. WoundClot was first offered for commercial applications in November 2014.
RedHawk stated, with the assistance of EcoGen Europe Ltd., its European pharmaceutical partner, that it has agreed to initially market WoundClot to hospitals and emergency rooms in the United Kingdom.
This release may contain forward-looking statements. Forward-looking statements are all statements other than statements of historical fact. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. The words "anticipate," "may," "can," "plans," "believes," "estimates," "expects," "projects," "targets," "intends," "likely," "will," "should," "to be," "potential" and any similar expressions are intended to identify those assertions as forward-looking statements.
Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties. In evaluating forward-looking statements, you should consider the various factors which may cause actual results to differ materially from any forward-looking statements including those listed in the "Risk Factors" section of our latest 10-K report. Further, the Company may make changes to its business plans that could or will affect its results. Investors are cautioned that the Company will undertake no obligation to update any forward-looking statements.
Daniel J. Schreiber, CEO
G. Darcy Klug, CFO
SOURCE: RedHawk Holdings Corp.